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Myasthenia gravis (MG) with antibodies to muscle-specific kinase (MuSK) is characterized by 
fluctuating fatigable weakness. In MuSK MG involvement of bulbar muscles, neck, shoulder and 
respiratory weakness is more prominent than in acetylcholine receptor (AChR) MG.  
MuSK autoantibodies are mainly of the IgG4 subclass, which is unable to activate complement, has 
low affinity for Fc-receptors, and is functionally monovalent. Therefore the pathogenicity of IgG4 
MuSK autoantibodies was initially questioned. 
A broad collection of in vitro, active immunization and passive transfer models has been developed 
that have shed light on the pathogenicity of MuSK autoantibodies. Passive transfer studies with 
purified IgG4 from MuSK MG patients confirmed that IgG4 is sufficient to reproduce clear clinical, 
electrophysiological as well as histological signs of myasthenia. In vitro experiments revealed that 
MuSK IgG4 autoantibodies preferably bind the first Ig-like domain of MuSK, correlate with disease 
severity and interfere with the association between MuSK and low density lipoprotein receptor-
related protein 4 (Lrp4) and Collagen Q. Some patients have additional IgG1 MuSK autoantibodies, 
but their role in the disease is unclear. All together this provides a rationale for epitope-specific or 
IgG4-specific treatment strategies for MuSK MG, and emphasizes the importance of the 
development of different experimental models. 
  
Introduction 
Autoimmune myasthenia gravis (MG) with antibodies to muscle-specific kinase (MuSK) is a 
neuromuscular disorder, which is clinically and immunologically different from the more prevalent 
MG with acetylcholine receptor (AChR) antibodies. Key clinical features are muscle weakness with 
prevalent involvement of cranial and bulbar muscles and more frequent respiratory crises than in 
AChR MG1. Compared to generalized AChR MG, a higher proportion of MuSK MG patients is 
reported to have a refractory course of the disease. More than 95% of the patients have ocular 
manifestations at some time during their disease, but bulbar muscles remain the most severely 
affected throughout the course of the disease. In contrast to the bulbar weakness, the ocular 
weakness in most cases quickly resolves with immunosuppressive treatment, and often do not 
reappear during MG relapses when the patients do suffer from severe bulbar weakness2. 
Interestingly, the observed pronounced sensitivity of bulbar muscles might be related to low 
endogenous levels of MuSK as compared to limb muscles such as the soleus muscle3. 
The diagnosis of MuSK MG is based on the combination of distribution of clinical weakness, results 
of electromyographical tests, and the presence of serum MuSK antibodies. The effect of 
acetylcholinesterase inhibitors, edrophonium or neostigmine, for diagnostic purposes is 
disappointing in one third of the patients. Also during treatment patients tend to have a poor 
response to oral acetylcholinesterase inhibitors, ranging from mild benefit to overt intolerance1. 
Most patients can be adequately managed with immunomodulatory therapies, using corticosteroids, 
and other immunosuppressive agents. Plasmapheresis or rituximab therapy have been shown to be 
very successful in the treatment of MuSK MG patients4-6.  
 
MuSK is a transmembrane tyrosine kinase that is expressed predominantly in skeletal muscle and 
concentrated at the postsynaptic membrane of the neuromuscular junction (NMJ). For a 
comprehensive review on the role of MuSK in NMJ development and maintenance see Burden et 
al.7. MuSK is concentrated at the central part of the muscle fiber and together with low density 
lipoprotein receptor-related protein 4 (Lrp4), docking protein 7 (or downstream of tyrosine kinase 7, 
Dok-7) and pre-synaptically released agrin stimulates AChR clustering and establishes a single NMJ at 
each muscle fiber. When MuSK is absent, synapses fail to form and mice die perinatally8. MuSK 
remains important in postnatal life for the maturation and maintenance of the adult neuromuscular 
synapse. Postnatal inactivation of MuSK causes loss of AChRs, disassembly of the postsynaptic 
organization and loss of innervation9. Moreover, mutations in MuSK cause congenital MG in 
humans10;11. 
 
The first clinical observations for a role of MuSK in myasthenia gravis 
The discovery of MuSK in 1993 and growing knowledge in the following years on its importance for 
NMJ formation and maintenance lead to testing MuSK as a candidate antigen in seronegative 
MG8;12;13. Indeed in 2001, in vitro experiments confirmed binding of serum antibodies to extracellular 
MuSK epitopes14. These early studies furthermore showed that these AChR antibody negative, MuSK 
antibody positive sera inhibited agrin-dependent AChR clustering in C2C12 myotube cultures 
suggesting their involvement in the pathogenesis of MG. Moreover, active immunization with the 
extracellular part of the human MuSK protein induced muscle weakness and associated changes in 
the neuromuscular junction in mice or rabbits15;16. In contrast, the first studies using biopsies of 
MuSK MG patients surprisingly failed to demonstrate clear evidence of synaptic impairment of loss 
of AChR 17;18. The study of Selcen et al. described one male patient who had typical facial and bulbar 
weakness and was positive for MuSK antibodies, but his endplates in the intercostal muscle biopsy, 
taken 13 years after disease onset, showed no AChR or MuSK loss at the NMJs. Another case report 
did find abnormalities in an intercostal muscle biopsy of a 29-year old female MuSK MG patient. In 
this case the biopsy was taken early in the disease at only nine months after the start of the 
disease19. In vitro electrophysiological and histological studies showed pre- and postsynaptic 
abnormalities. Histology revealed partially denervated postsynaptic areas and some degeneration of 
postsynaptic folds. However, only a qualitative analysis was possible due to the low number of 
synapses that were available. 
In a study using muscle biopsies of 10 Japanese MuSK MG patients the endplate AChR density was 
not significantly decreased, and complement C3 was detected at the endplate in only two of eight 
cases18. The authors concluded that MuSK antibodies did not appear to cause substantial AChR loss, 
complement deposition, or morphological damage. A possible drawback of this study was that it 
used motor point biopsies from the biceps brachii, a muscle that usually is less severely affected in 
MuSK MG. 
Importantly, serum IgG MuSK autoantibodies correlate with disease severity20-22 and placental 
transfer of antibodies from mother to her child induces transient MG in the neonate23;24. 
In conclusion, clinical correlations, experimental data on the function of the MuSK protein in animals 
and in vitro preparations, as well as the results of active immunization experiments form clear 
evidence for pathogenicity of MuSK antibodies in autoimmune MG. In contrast, the sparsely 
available histological studies of human endplates failed to convincingly show a decrease in MuSK or 
AChR to an extent that it could explain the electrophysiological dysfunction found in the same 
neuromuscular synapses. Passive transfer studies, using human MuSK serum antibodies, have 
proven essential in obtaining more detailed understanding of the pathophysiology of MuSK MG and 
will be discussed below (Table). 
 
Passive transfer of IgG from “seronegative” patients 
Before the discovery of MuSK antibodies in 200114, there were already indications that some MG 
patients might have other serum antibodies causing similar patterns of muscle weakness. In 10-15% 
of the MG patients no AChR antibodies were found, while these patients had characteristic features 
of MG on electromyographical examination or showed clinical improvement after plasmapheresis or 
immunosuppressive treatment. One of the earliest studies used plasma obtained by plasmapheresis 
from 8 patients with signs and symptoms of MG, but in whom serum AChR antibodies had been 
persistently undetectable by radioimmunoprecipitation assay or by testing inhibition of α-
bungarotoxin binding25. Remarkably, six of these patients had bulbar weakness, of whom four with 
severe bulbar weakness and four patients required assisted ventilation at some time point during 
their disease. This pattern fits well with the now well-known clinical features of MuSK MG1;5;26. 
Indeed, a later study from the same group confirmed that most sera were subsequently tested 
positive for MuSK antibodies27. 
Crude immunoglobulin fractions prepared by precipitation with 45% ammonium sulphate followed 
by extensive dialysis were used for passive transfer studies to BKTO mice, an outbred strain25. Pooled 
IgG from healthy individuals was used as a negative control, and IgG from AChR MG patients as 
positive control. Mice were injected intraperitoneally with 60 mg IgG per day for 3 days. Eighteen 
hours after the last injection the diaphragms were studied. The diaphragms of the mice were studied 
using in vitro contraction tests, in which supramaximal stimuli at 3 Hz were given through the nerve 
ending attached to the muscle. Using a normal perfusion solution no decrement of the twitch 
contraction force was found comparing the amplitude of the fifth response with that of the first in 
that train of stimuli. However, using a low dose of tubocurarine of 0.6 μg/ml a clear contraction 
force decrement was seen in the diaphragms of the mice treated with IgG from the “seronegative” 
patients. The number of AChRs was lower than in the control mice, but the decrease was much less 
than that of the AChR MG IgG treated mice, suggesting it might be a secondary effect due to 
antibodies interfering with other molecules than the AChR itself, e.g. MuSK or Lrp4. These early 
experiments suggested that MG patients without AChR serum antibodies do have antibodies binding 
to determinants at the neuromuscular junction other than the AChR. In these experiments, mice 
were treated for only three days, and in retrospect that is probably too short to see a profound 
effect. None of the mice showed clinical signs of disease. Also in a second set of experiments, in 
which mice were treated up to 15 days with either purified IgG or whole plasma, no clinical 
weakness was observed28. In these latter experiments again plasma or IgG fractions were used for 
passive transfer studies to BKTO mice. With IgG from 5 of 6 patients considerably reduced miniature 
endplate potential (MEPP) amplitudes were found in the mice after 15 days of injection. After 3 days 
of treatment, less or no MEPP amplitude reduction was found, indicating that for most IgG 
preparations or plasmas at least 7 to 15 days were necessary before an effect on the NMJs could be 
detected by ex vivo electrophysiology assays. 
 
Passive transfer of IgG from MuSK MG patients 
Several years after the discovery of MuSK auto-antibodies passive transfer studies from well-
documented MuSK MG patients were described29. Total IgG purified from plasmapheresis material 
from three patients was used to perform passive transfer studies in two strains of mice. Mice were 
treated with 45 mg/day of IgG during up to 14 days. Passive transfer of IgG to FVB/NJ mice was not 
able to induce clinical muscle weakness nor weight loss, while C57BL/6J mice showed clear 
weakness, including chin down, flaccid tail and limb weakness. Initially, this appeared only after 
exercise, but later on also at rest. Weight loss appeared typically after 7 days of daily IgG injections. 
In active immunization models some strains of mice were reported to be more susceptible to MG 
than others15. Interestingly, mice injected for 14 days with MuSK MG patient IgG displayed reduced 
levels of post-synaptic AChR and a reduced apposition of presynaptic and postsynaptic 
neuromuscular structures. These findings were more pronounced in mice that showed more muscle 
weakness29. 
A passive transfer study with intramuscular injections found that MuSK MG plasma decreased the 
size of new endplates formed upon muscle regeneration after pretreatment with notexin, a 
myotoxic snake toxin. Furthermore, MuSK plasma injections caused impairment of muscle 
contraction in vitro in the presence of reduced calcium in the medium30. 
These findings together with the results of the active immunization studies, correlation with disease 
severity and therapeutic effect of plasmapheresis and immunosuppressive treatment in MuSK MG 
patients, contribute to the evidence on MuSK autoantibody pathogenicity and identify them as a 
helpful diagnostic tool. 
The exact target and pathophysiological mechanisms of MuSK MG remained elusive, until in 2011 
and 2012 several papers provided new information. Using in vitro studies, Kawakami et al. found 
that MuSK IgG blocks the binding of Collagen Q (ColQ) to MuSK31. In their passive transfer model 
they injected purified total IgG from a MuSK MG patient to C57BL/6J mice during 14 days. No 
weakness or weight loss was described, but they found that anchoring of ColQ was compromised, 
while they observed a less prominent effect on the expression of MuSK and AChR at the endplates. 
These results would predict endplate acetylcholinesterase (AChE) deficiency in MuSK MG patients, 
and might explain the increased sensitivity of MuSK MG patients for acetylcholinesterase inhibitors1. 
However, a previous biopsy study on intercostal muscles did not report an AChE deficiency17. To 
explain the various results of the experimental studies in vitro, in mice and the human biopsies, it 
was suggested that MuSK IgG behaves differently in humans and does not block binding of ColQ to 
the NMJ to such an extent that it induces clinical symptoms. 
Around the same time we showed that purified IgG4 from MuSK MG patients binds to mouse NMJs 
and can induce severe paralysis32.  MuSK antibodies are predominantly of the IgG4 isotype, and since 
IgG4 (MuSK) antibodies are functionally monovalent and do not activate complement, this 
pathogenic effect was surprising33-35. Purified MuSK MG patient IgG4 was passively transferred to 
immunodeficient NOD/SCID mice for up to 14 consecutive days. MG symptoms developed usually 
after 7-9 days depending on the patient and the dose. This model has several advantages compared 
to the abovementioned animal models. Due to their immunodeficiency these mice do not need any 
additional immunosuppressive drug treatment with potential toxic side effects to prevent the 
formation of neutralizing antibodies. The use of purified IgG4 allows more variation in dosing of the 
antibodies. Furthermore, the non-IgG4 fraction of the same patients can be tested in parallel. 
Passive transfer models using purified total IgG are limited by the maximum volume of 1 ml that is 
allowed for intraperitoneal injection in mice. This again limits the amount of IgG to typically 45-60 
mg that can be injected at one time point, as higher IgG concentrations are generally not soluble. 
IgG4 constitutes about 5-14% of the total IgG, from which one can calculate that the preparations of 
total MuSK IgG contain about 2 to 8 mg of MuSK IgG4. Indeed, 4 mg of purified MuSK IgG4 induced 
overt and consistent clinical weakness in mice32. All together these studies identify mouse strain, 
dosing and the duration of treatment, as important reasons why earlier experiments using total 
purified IgG were not always successful in inducing clinical disease in mice. 
In line, Viegas et al. observed no weight loss or overt weakness in mice that received 5 days of 50 mg 
of total IgG from MuSK MG patients36. Interestingly, they described that MuSK antibody levels in 
these mice were very similar to patient plasma levels, although five to 10-fold lower than that of 
actively MuSK immunized mice. It has not been studied in detail if treatment for 3 to 5 days with a 
high dose MuSK autoantibodies is sufficient to induce disease. Because the indirect effect of MuSK 
on AChR function, a period of at least one week could be the minimum time needed for MuSK 
antibodies to have a clinical overt effect on the muscles in mice after passive transfer. Pulse-labelling 
of NMJs with α-bungarotoxin of mice treated with MuSK MG patient IgG showed a reduction of 6.6% 
of AChR per day amounting to 40% after 6 days37. The decline of AChR density corresponded with 
the progressive decline of electromyographic read outs that represent MG38. All together, these 
experiments suggest that a dose of at least 45 mg/day per mouse of total IgG for a duration of at 
least 7 days is necessary to induce weakness and weight loss in the mice (Table). 
The passive transfer studies in NOD/SCID mice showed that the purified IgG4 fraction from MuSK 
MG patients induced clinical disease, reduced the density and increased fragmentation of the AChRs 
(figure 1), and caused severe reduction of postsynaptic acetylcholine sensitivity32. Interestingly, the 
normal presynaptic homeostatic response, consisting of a compensatory transmitter release 
upregulation, as normally seen in AChR MG39, was absent. Another interesting finding was that the 
IgG1-3 fraction of the same MuSK MG patient did not induce any signs of in vivo disease and 
functional or histological NMJ aberrations in dissected muscles. A possible explanation for the lack of 
effect from IgG1-3 IgG from MuSK MG patients could be the absence of complement. Therefore 
healthy human serum was added as a source of complement into NOD/SCID mice that were treated 
for 10-18 days. This however also did not result in any signs of weakness or in vitro 
electrophysiological abnormalities. The fact that the IgG1-3 fraction contains lower MuSK antibody 
titres forms an additional explanation. 
Thus, IgG4 plays a major role in the pathogenesis of MuSK MG. Still, some MuSK binding capacity is 
present in the IgG1-3 serum fraction of some MuSK MG patients, and these antibodies are also 
capable of inhibiting agrin-induced AChR clustering40. Therefore complement activation and a role 
for IgG1-3 MuSK autoantibodies in the disease cannot be excluded40;41. However, in general the 
concentration of MuSK binding IgG1-3 autoantibodies appears to be too low to have a clinically 
relevant impact. 
 
Treatment of MuSK MG in passive transfer models 
Pyridostigmine and 3,4-diaminopyridine (3,4-DAP) were tested in a passive transfer model of MuSK 
MG42. Pyridostigmine is used as a first line symptomatic treatment for patients with MG43. It inhibits 
the action of acetylcholinesterase, thereby prolonging the action of acetylcholine on postsynaptic 
AChRs. 3,4-DAP enhances acetylcholine release from the presynaptic nerve terminal, and is used in 
Lambert-Eaton myasthenic syndrome or in patients with congenital MG44. Pyridostigmine prolongs 
the activity of acetylcholine in the synaptic cleft, while 3,4-DAP increases the number of quanta that 
are released presynaptically. This results in different and to some extent opposing effects on the 
NMJ. 
The activation of MuSK by neural agrin and Lrp4, and that of the AChR by acetylcholine, deliver 
competing signals to the NMJ that regulates assembly or disassembly of AChR clusters. MuSK 
contributes to the assembly and activation of AChR clusters, while activation of the AChRs drives 
intracellular pathways that promote dismantling of AChR clusters. Morsch et al. showed that 
systemic delivery of pyridostigmine to mice receiving daily injections of total IgG from MuSK MG 
patients exacerbated the disease, and induced structural alterations and functional impairment at 
diaphragm NMJs42. Mice receiving lower doses of MuSK auto antibodies (25 mg per day), that usually 
does not lead to clinically overt weakness, showed generalized weakness after a 9 day treatment 
with pyridostigmine. The same dose of pyridostigmine did not harm control mice receiving normal 
human IgG. Interestingly, MuSK autoantibodies have been demonstrated to disrupt the interaction 
between MuSK and ColQ31. Loss of endplate acetylcholinesterase could potentiate any harmful 
prolonged activation of endplate AChRs by pyridostigmine mediated increase in available 
acetylcholine in MuSK MG. In contrast, 3,4-DAP improved neuromuscular transmission in the 
diaphragm after one week of treatment42. A subcutaneous minipump delivered an effective dose of 
about 16 mg/kg/day pyridostigmine or 3,4-DAP at 8 mg/kg/day. A MG patient using 6 x 60 mg of 
pyridostigmine per day, uses typically about 5 mg/kg per day, while 3,4-DAP at a daily dose of 70 mg 
would result in 1 mg/kg/day. It is difficult to directly compare mice and men, but the dose of 
pyridostigmine or 3,4-DAP in mice was likely at a therapeutically relevant level. 
Drugs that activate beta-adrenergic receptors, among which ephedrine and albuterol, offer a 
therapeutic benefit in certain forms of congenital MG45;46. Ephedrine has also been used in 
autoimmune MG47 and recently it was successful in a small n-of-1 trial48. Ghazanfari et al. also used 
the passive transfer MuSK MG mouse model to test the effect of a beta2-adrenoceptor agonist 
albuterol49. Mice were treated with 25 mg total IgG from a MuSK MG patient during 15 days. In this 
model weight loss and weakness typically developed between 12 and 15 days. Treatment with 
albuterol (8 mg/kg/day) during two weeks reduced the clinical signs of disease. Surprisingly, 
endplate potential amplitudes did not increase in the treated group and loss of AChRs was not 
prevented. The possibility was considered that albuterol reduced the clinical defects through a direct 
effect on the contractility of the muscle fibers with still intact neuromuscular synaptic transmission. 
On the other hand, albuterol significantly reduced the degree of fragmentation of AChR clusters and 
increased the extent to which the remaining receptor clusters were covered by presynaptic nerve 
terminals. 
Further experiments suggested that forced expression of MuSK could help to slow down the loss of 
postsynaptic AChRs in MuSK MG50. This was tested by injecting an adeno-associated viral vector 
encoding MuSK in the tibialis anterior muscle of mice. Next, the mice were challenged with 35 mg of 
total IgG from MuSK MG patients during 11 days. In the treated mice more MuSK and AChR were 
retained at the endplates. Electromyographical recordings revealed less impairment in the treated 
muscle compared to the contralateral leg. 
 
In conclusion, the passive transfer model of MuSK MG has proven very useful to gain more insight in 
the pathogenesis of the disease, and in testing the potential therapeutic benefit of several readily 
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Table. Summary of published passive transfer models for MuSK MG 
Study Material Dose Duration of 
treatment 
Clinical signs of MG in mice Laboratory signs of MG in mice MG variant in 
donor patients 
Mossman, 1986 IgG 60 mg/day 3 days  None  Reduced safety factor  SNMG 




3 to 7 days 
7 to 15 days 
 None  Reduced MEPP amplitude SNMG 
Cole, 2008 IgG 45 mg/day 14 days  Weakness  and weight loss in C57BL/J6 
mice 
 None in FVB/NL mice 
 Reduced and fragmented  endplate AChR 
staining  
 Reduced synaptic alignment 
 Denervation 
MuSK MG 
ter Beek, 2009 plasma 40 microliter 21 days, twice daily, 
on weekdays 
 None Reduced safety factor 
Reduced endplate size 
MuSK MG 
Kawakami, 2011 IgG 40 mg/day 15 days  None described  Reduced endplate AChR area 
 Reduced AChE and ColQ staining 
MuSK MG 
Morsch, 2012 IgG 45 mg/day 14 days  Weakness 
 Weight loss  
 Reduced MEPP and EPP amplitudes 
 Decrement of CMAP at 3 Hz 
MuSK MG 
Viegas, 2012 IgG 50 mg/day 5 days  None  Reduced  MEPP and EPP amplitudes (in weak 
mice) 
MuSK MG 
Klooster, 2012 IgG4, IgG1-3  0.5-6 mg/day 14 days  Weakness 
 Weight loss 
 Decrement of CMAP at 10 Hz 
 Reduced MEPP and EPP amplitudes 
 Reduced safety factor 
Reduced and  fragmented AChR staining 
MuSK MG 
Ghazanfari, 2014 IgG 45 mg/day 14 days  Weakness  Reduced phophorylation 
 Loss of AChR from endplate 
MuSK MG 
 
